Article
Analysis of Human Leukocyte Antigen DR Alleles, Immune-Related Adverse Events, and Survival Associated With Immune Checkpoint Inhibitor Use Among Patients With Advanced Malignant Melanoma.
JAMA network open - 1 Dec 2022
Akturk Halis Kaan, Couts Kasey L, Baschal Erin E, Karakus Kagan E, Van Gulick Robert J, Turner Jacqueline A, Pyle Laura, Robinson William A, Michels Aaron W
Abstract excerpt
Importance: Treatment with immune checkpoint inhibitors (ICIs) has increased survival in patients with advanced malignant melanoma but can be associated with a wide range of immune-related adverse events (irAEs). The role of human leukocyte antigen (HLA)-DR alleles in conferring irAE risk has not been well studied. Objective: To evaluate the association between irAEs and treatment response, survival, and the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.